7BIO
CAS No. 916440-85-2
7BIO( —— )
Catalog No. M27496 CAS No. 916440-85-2
7-bromoindirubin-3'-oxime (7BIO) is a caspase independent nonapoptotic cell death inducer. 7BIO is an inhibitor of FLT3, DYRK1A, DYRK2, Aurora B and Aurora C kinases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 42 | In Stock |
|
| 5MG | 36 | In Stock |
|
| 10MG | 55 | In Stock |
|
| 25MG | 112 | In Stock |
|
| 50MG | 175 | In Stock |
|
| 100MG | 277 | In Stock |
|
| 200MG | 393 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name7BIO
-
NoteResearch use only, not for human use.
-
Brief Description7-bromoindirubin-3'-oxime (7BIO) is a caspase independent nonapoptotic cell death inducer. 7BIO is an inhibitor of FLT3, DYRK1A, DYRK2, Aurora B and Aurora C kinases.
-
Description7-bromoindirubin-3'-oxime (7BIO) is a caspase independent nonapoptotic cell death inducer. 7BIO is an inhibitor of FLT3, DYRK1A, DYRK2, Aurora B and Aurora C kinases.
-
In Vitro7BIO (1 and 10 μM; 24 hours) has neuroprotective effects and can prevent, but cannot rescue Aβ1?42 oligomer-induced cell death in SH-SY5Y cells. Cell Viability AssayCell Line:SH-SY5Y cellsConcentration:1 and 10 μMIncubation Time:24 hoursResult:Inhibit Aβ oligomer-induced neuronal death. 7BIO prevented, but did not rescue Aβ1?42 oligomer-induced cell death in SH-SY5Y cells.
-
In Vivo7Bio (2.3, 7.0, and 23.3 μg/kg; bilateral ventricle injection) significantly attenuates Aβ oligomer-induced impairment of recognition, spatial learning and memory in mice.7Bio (2.3, 7.0, and 23.3 μg/kg; bilateral ventricle injection) decreases Aβ oligomer-induced increase of TNF-α and IL-6 production in the brain and the expression of synapsin-1 and PSD-95 in the hippocampal region of mice.7Bio (2.3, 7.0, and 23.3 μg/kg; bilateral ventricle injection) attenuates Aβ oligomer-induced increase expression of pTau, activation of microglia and astrogliosis in the brain of mice.7Bio (2.3, 7.0, and 23.3 μg/kg; bilateral ventricle injection) prevents decreased expression of pSer9-GSK3β and has no significant effects on the Tau protein level. Animal Model:8 weeks mice (30 g)Dosage:2.3, 7.0, and 23.3 μg/kg Administration:bilateral ventricle injection Result:Attenuates Aβ oligomer-induced impairment of recognition, spatial learning and memory in mice.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetFLT
-
Recptorglutamine synthetase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number916440-85-2
-
Formula Weight356.179
-
Molecular FormulaC16H10BrN3O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (701.91 mM)
-
SMILESO\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2c1cccc2Br
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Premakumar R, Sorger GJ, Gooden D. Repression of nitrate reductase in Neurospora studied by using L-methionine-DL-sulfoximine and glutamine auxotroph gln-1b. J Bacteriol. 1980;143(1):411-415.
molnova catalog
related products
-
FLT3-IN-4
FLT3-IN-4 (FLT3 inhibitor 9u) is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3;?IC50=7 nM) inhibitor ,for treating acute myelogenous leukemia.
-
BGB-102
BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3, which may be useful in the study of macular degeneration and diseases associated with genetic disorders and malformations.
-
FLT3-IN-10
FLT3-IN-10 (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). FLT3-IN-10 shows the potential for the treatment of FLT3-mutated acute myeloid leukemia (AML).
Cart
sales@molnova.com